Randomized Phase II Trial of Vincristine-Irinotecan With or Without Temozolomide, in Children and Adults With Relapsed or Refractory Rhabdomyosarcoma: A European Paediatric Soft Tissue Sarcoma Study Group and Innovative Therapies for Children With Cancer Trial.
Anne-Sophie DefachellesEmilie BogartMichela CasanovaJohannes Hendrikus Maria MerksGianni BisognoGiuseppina CalaresoSoledad Gallego MelconSusanne Andrea GatzMarie-Cécile Le DeleyKieran McHughAlicia ProbstNathalie RocourtRick R van RijnKeith WheatleyVeronique Minard ColinJulia C ChisholmPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2021)
The addition of temozolomide to VI improved chemotherapy efficacy for patients with relapsed RMS, with manageable increase in toxicity. VIT is considered the new standard treatment in these patients in the European paediatric Soft Tissue Sarcoma Group and will be the control arm in the next randomized trial.
Keyphrases
- newly diagnosed
- acute lymphoblastic leukemia
- end stage renal disease
- phase iii
- acute myeloid leukemia
- open label
- young adults
- emergency department
- intensive care unit
- multiple myeloma
- phase ii
- diffuse large b cell lymphoma
- hodgkin lymphoma
- ejection fraction
- chronic kidney disease
- clinical trial
- placebo controlled
- double blind
- oxidative stress
- prognostic factors
- papillary thyroid
- randomized controlled trial
- squamous cell carcinoma
- patient reported outcomes
- rectal cancer
- chemotherapy induced